Atom Bioscience is a research-based pharmaceutical company engaged in new drug discovery and development on treatments for inflammatory and metabolic diseases.
Among our drugs now in development is ABP-671, a novel compound for gout treatment. APB-671 has completed Phase 1 clinical trials in the United States and 2a clinical trials in Australia. Atom Bioscience is advancing ABP-671 to global Phase 3 trials and commercialization.
Our novel compound ABP-6016 is currently under pre-clinical development for NASH and gastric cancer. Atom Bioscience expects ABP-6016 to enter clinical trials soon.
Atom Bioscience Management Team
Atom Bioscience Investors
Since 2012, Dr. Shi and his experienced management team have raised about $87 million USD to advance ABP-671 and ABP-6016 along with other compounds in the company’s pipeline. The company closed its latest round of financing, a Series C, in December 2021 for $47 million USD led by Kingray Capital and GTJA Investment Group.